Colorectal Cancer Metastatic

Oncology·MeSH: Disease

Prevalence

135.0 / 100K

Incidence

36.0 / 100K/yr

6 drugs in development·4 companies·15 clinical trials

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
FOLFOX	KYNTRA BIO INC. (KYNB)
IBI351, cetuximab β combined with FOLFIRI	IGM Biosciences, Inc. (IGMS)
Systemic therapy	IGM Biosciences, Inc. (IGMS)

Phase 2(2)

Drug	Company
FLOX	ENANTA PHARMACEUTICALS INC (ENTA)
FOLFOX regimen	KYNTRA BIO INC. (KYNB)

Early Phase 1(1)

Drug	Company
experimental	VERTEX PHARMACEUTICALS INC / MA (VRTX)

BioSniper tracks 6 drugs in development for Colorectal Cancer Metastatic across 4 companies.

There are 15 clinical trials targeting Colorectal Cancer Metastatic tracked by BioSniper.

The estimated prevalence of Colorectal Cancer Metastatic is approximately 135.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.